Skip to main content
. 2017 May 22;8:15497. doi: 10.1038/ncomms15497

Figure 3. Expression of miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p in an animal model of MDD and post-mortem human brain samples.

Figure 3

(a) Experimental design. Mouse model of MDD. Baseline (d0), 14 days of treatment (d14), responders (RES), nonresponders (NRES), susceptible (Susc) and Control (Ctrl). *Number of significant miRNAs. **Mice were treated with imipramine or saline solution. Resilient mice were not studied. (b) Differential expression of miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p after 14 days of imipramine treatment in mice by NanoString nCounter Digital Analyzer. *P<0.05; **P<0.01; ‡P<0.1. (c) Quantitative real-time PCR (qRT-PCR) expression data of miR-146a-5p, miR-146b-5p, miR-24-3p and miR-425-3p in vPFC of post-mortem brains of subjects with MDD and controls. *P<0.05; **P<0.01.